Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Farydak's Approval last Feb Should Give Us Hope:
View:
Post by SteveMcM1 on Nov 21, 2015 2:18pm

Farydak's Approval last Feb Should Give Us Hope:

https://www.myelomabeacon.com/news/2015/02/23/farydak-panobinostat-fda-approval/

An Eventful Road To Approval

The FDA’s decision to approve Farydak is likely to come as a surprise to many people. The drug was re­viewed during an FDA advisory committee meeting in early November last year, but failed to gain the support of the committee, which voted 5 to 2 against recommending the drug for FDA approval (see related Beaconnews).

The FDA typically makes approval decisions that reflect the recommendations of its advisory committees. Thus, there was widespread pessimism about Farydak’s chances for FDA approval following the early November advisory committee vote.

Some of that pessimism dissipated, however, when the FDA announced late in November that it was giving itself an extra three months to reach a decision on Farydak’s approval application. Had it not taken that step, the agency would have had to announce its decision by the end of November (see related Beacon news).

There are many reasons why the FDA can decide to delay an approval decision. However, in this case, one reasonable interpretation was that the agency was unwilling to make a quick decision based on its advisory committee’s recommendation.

There also was speculation at the time that one option the FDA might be considering was an approval of Farydak that was more restrictive than what Novartis requested in its approval application.

This, in fact, is what has happened.

Comment by txbioinv on Nov 21, 2015 2:28pm
nice find
Comment by Ghanam on Nov 21, 2015 6:31pm
Good Find, Steve. Here's another one, worth reading: How To Save A Drug After A Negative Panel Review? Narrow The Indication
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities